Novo Nordisk risks weight-loss price war as discount pressures deepen

Core Viewpoint - Novo Nordisk's new CEO faces challenges due to "unprecedented" price pressure leading to significant cost reductions for the Wegovy drug [1] Company Summary - Novo Nordisk is experiencing a price war that may negatively impact its profitability and market position [1] - The company is compelled to lower the price of its blockbuster drug Wegovy, which is a treatment for obesity [1] Industry Summary - The pharmaceutical industry, particularly in the obesity treatment sector, is witnessing intense price competition [1] - This price pressure could reshape market dynamics and affect the strategies of companies involved in obesity drug development [1]